How To Use HCPCS Code C2641

HCPCS code C2641 describes a brachytherapy source that is non-stranded and contains palladium-103. This code is used to identify a specific type of radioactive material that is used in the treatment of various types of cancer. Brachytherapy is a form of radiation therapy where radioactive sources are placed directly into or near the tumor site to deliver a targeted dose of radiation. The use of palladium-103 as the radioactive source allows for precise and localized treatment.

1. What is HCPCS C2641?

HCPCS code C2641 is used to identify a brachytherapy source that contains palladium-103. This code is specific to non-stranded sources, which means that the radioactive material is not in the form of a strand or wire. The use of this code indicates that the provider is utilizing palladium-103 as the radioactive source for brachytherapy treatment.

2. Official Description

The official description of HCPCS code C2641 is “Brachytherapy source, non-stranded, palladium-103, per source.” The short description for this code is “Parenteral supp not othrws c.” This description accurately reflects the nature of the code and the specific type of brachytherapy source it represents.

3. Procedure

1. The brachytherapy procedure begins with the placement of the non-stranded palladium-103 source into or near the tumor site.
2. The source is carefully positioned to ensure precise targeting of the radiation dose.
3. The radioactive material emits radiation that destroys cancer cells and shrinks tumors.
4. The duration of the treatment depends on the specific case and the prescribed dose.
5. After the treatment is complete, the source is removed.

4. When to use HCPCS code C2641

HCPCS code C2641 should be used when a healthcare provider is performing brachytherapy using a non-stranded palladium-103 source. This code is specific to the use of palladium-103 and indicates that the provider is utilizing this particular radioactive material for the treatment of cancer. It is important to ensure that the documentation supports the use of this specific code and that the treatment meets the criteria for brachytherapy using palladium-103.

5. Billing Guidelines and Documentation Requirements

When billing for brachytherapy using HCPCS code C2641, healthcare providers should ensure that the documentation supports the use of palladium-103 as the radioactive source. This may include the type and dosage of the source used, as well as the specific tumor site being treated. It is important to follow the guidelines set forth by Medicare and other insurance carriers to ensure accurate and timely reimbursement.

6. Historical Information and Code Maintenance

HCPCS code C2641 was added to the Healthcare Common Procedure Coding System on January 01, 1985. Since its addition, there have been no maintenance actions taken for this code, as indicated by the action code N, which means no maintenance for this code. This code has been in use for many years and has remained unchanged since its inception.

7. Medicare and Insurance Coverage

HCPCS code C2641 is eligible for coverage by Medicare and other insurance carriers. The pricing indicator code 57 indicates that this code is priced by other carriers, meaning that the reimbursement rate may vary depending on the specific carrier. The multiple pricing indicator code A indicates that this code is not applicable as HCPCS priced under one methodology. It is important to verify coverage and reimbursement rates with the respective insurance carriers to ensure accurate billing and reimbursement.

8. Examples

Here are five examples of when HCPCS code C2641 should be billed:

1. A patient with prostate cancer undergoes brachytherapy using a non-stranded palladium-103 source.
2. A patient with cervical cancer receives brachytherapy treatment with a non-stranded palladium-103 source.
3. A patient with breast cancer undergoes brachytherapy using a non-stranded palladium-103 source after lumpectomy.
4. A patient with lung cancer receives brachytherapy treatment with a non-stranded palladium-103 source.
5. A patient with head and neck cancer undergoes brachytherapy using a non-stranded palladium-103 source.